Summary

162.98 -1.80(-1.09%)07/17/2025
Johnson & Johnson (JNJ)

Key Facts


1 Day1 Week1 Month3 Months6 Months1 Year5 Years
0.413.886.964.3912.707.4825.56


Last 730 data points are shown. To view all data, Upgrade to PRO plan!


Fundamental Ratings
CategoryRating
Main RatingB+
Recommended RatingNeutral
DCFBuy
ROEStrong Buy
ROAStrong Buy
Debt/EquityStrong Sell
P/ESell
P/BSell


Earnings
  • JNJ reported last earnings on 2025-07-16 after the market.
  • An EPS of $2.77 was observed compared to an estimated EPS of $2.68, resulting in a surprise value of $0.09.
  • A revenue of $23,743 million was observed compared to an estimated revenue of $22,854 million, resulting in a surprise value of $889 Million.


  • Trading Data
    Close163.65
    Open163.93
    High165.09
    Low163.37
    Volume6,943,337
    Change0.67
    Change %0.41
    Avg Volume (20 Days)9,241,203
    Volume/Avg Volume (20 Days) Ratio0.75
    52 Week Range138.69 - 168.54
    Price vs 52 Week High-2.90%
    Price vs 52 Week Low18.00%
    Range0.00
    Gap Up/Down-2.94
    Profitibility
    Market Capitalization (Mln)373,735
    Revenue per share27.6483
    Net Income per share9.3675
    Dividend Yield0.0308
    Dividend Share502.00%
    Valuations
    Enterprise Value0.00%
    PE Ratio17.3984
    PB Ratio0.0000
    PTB Ratio0.0000
    Liquidity
    Debt/Equity Ratio0.0000
    Net Debt/EBIDTA Ratio0.0000
    Current Ratio0.0000
    Enterprise Value and Cash Flow
    EV/Sales Ratio0.0000
    EV/EBIDTA Ratio0.0000
    EV/Free Cash Flow Ratio0.0000


    07/18 12:10 EST - zacks.com
    J&J Expects Oncology Sales of USD 50B by 2030: Can It Achieve the Goal?
    JNJ eyes $50B in oncology sales by 2030, driven by drugs like Darzalex, Erleada, new launches including Carvykti and Tecvayli, and its cancer pipeline.
    07/18 11:42 EST - proactiveinvestors.com
    Spravato sales momentum underscores market potential for psychedelics, atai Life Sciences seen as key beneficiary
    Sales of Johnson & Johnson (NYSE:JNJ)'s esketamine nasal spray Spravato grew sequentially in the second quarter, marking a positive sign for the broader psychedelics sector, according to Jefferies analysts. Spravato sales grew 29% quarter-over-quarter to $414 million worldwide.
    07/17 19:47 EST - youtube.com
    JNJ gave us a manual on how to spot a stock that can soar after earnings, says Jim Cramer
    'Mad Money' host Jim Cramer talks how to react when surprise stock pops happen.
    07/17 16:37 EST - benzinga.com
    Stock Of The Day: Breakout In Johnson & Johnson
    Johnson & Johnson JNJ stalled out at resistance around the $165 level. There tends to be resistance at price levels that had previously been resistance.
    07/17 14:26 EST - marketbeat.com
    Want Steady Income? 3 Top Dividend Stocks for July 2025
    Earnings season is synonymous with market volatility. Growth-oriented investors may love trading the ups and downs, but more risk-averse investors may look for ways to generate solid returns balanced by steady cash flow.
    07/17 12:40 EST - seekingalpha.com
    Johnson & Johnson: The Worst Is Baked In
    J&J's diversified business, robust pipeline, and strong free cash flow provide stability despite ongoing legal overhang from talcum powder claims. Legal risks remain a near-term headwind, but I believe any settlement will be manageable for J&J's financial strength and present a buying opportunity....
    07/17 12:01 EST - zacks.com
    ETFs to Gain on JNJ's Solid Q1 Earnings & Upbeat Outlook
    IHE, PPH, XLV, IYH and FTXH could gain as JNJ lifts 2025 outlook and dividend after strong Q2 earnings beat.
    07/17 09:32 EST - benzinga.com
    Johnson & Johnson Analysts Raise Their Forecasts After Upbeat Earnings
    Johnson & Johnson JNJ posted better-than-expected quarterly earnings and raised its FY2025 earnings guidance on Wednesday.
    07/17 08:00 EST - prnewswire.com
    Johnson & Johnson receives U.S. FDA Priority Review for TAR-200 NDA in high-risk non-muscle invasive bladder cancer
    New Drug Application supported by results from the Phase 2b SunRISe-1 study RARITAN, N.J. , July 17, 2025 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today announced that the U.S. Food and Drug Administration (FDA) granted Priority Review to the New Drug Application (NDA) filed for TAR-200, an...
    07/17 06:05 EST - fool.com
    Johnson & Johnson's Healthy 3.3%-Yielding Dividend Is a Very Safe Way to Make Passive Income
    Johnson & Johnson (JNJ 6.21%) has been an extremely reliable dividend stock for decades. The healthcare behemoth has raised its payment for 63 straight years, including by 4.8% earlier this year.
    07/17 04:37 EST - fool.com
    Is Johnson & Johnson a Good Dividend Stock to Buy Now?
    For decades, Johnson & Johnson (JNJ 6.21%) stock was favored by investors seeking steady gains. Looking at its post-COVID-19 performance, though, steady gains aren't what investors received.
    07/16 18:01 EST - fool.com
    3 Top Dividend Stocks Yielding More Than 3% That You Shouldn't Hesitate to Buy Right Now
    With the S&P 500 back in rally mode, the dividend yield on the broad market index is falling. It was recently down to around 1.2%, which is approaching its record low last hit a quarter-century ago.
    07/16 17:40 EST - investopedia.com
    S&P 500 Gains and Losses Today: Johnson & Johnson Stock Jumps; Universal Health Services Shares Slide
    Major U.S. equities indexes ticked higher Wednesday as President Donald Trump refuted reports that he is planning the immediate dismissal of Federal Reserve Chair Jerome Powell and questions about his legal ability to do so.
    07/16 16:26 EST - zacks.com
    Johnson & Johnson (JNJ) Q2 Earnings and Revenues Top Estimates
    Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
    07/16 16:20 EST - zacks.com
    Johnson & Johnson (JNJ) Surpasses Q2 Earnings and Revenue Estimates
    Johnson & Johnson (JNJ) came out with quarterly earnings of $2.77 per share, beating the Zacks Consensus Estimate of $2.66 per share. This compares to earnings of $2.82 per share a year ago.
    07/16 16:16 EST - marketbeat.com
    JNJ's Stock Price Is Back in Rally Mode—The Time to Buy Is Now
    After years of post-COVID-19 normalization and the impact of its Kenvue spinoff, Johnson & Johnson's NYSE: JNJ stock price is back in rally mode. It is still early in the game, but the Q2 results affirm that growth is back, acceleration is happening and is expected to continue in the back half...
    07/16 16:00 EST - youtube.com
    JNJ Technicals & Takeaways After Earnings, Healthcare Reaching Key Levels
    Johnson & Johnson (JNJ) shares popped after earnings that showed strength for the healthcare company. Rick Ducat dives into the stock chart to highlight how Johnson & Johnson is tapping a notable resistance level backed by bullish signals.
    07/16 15:36 EST - seekingalpha.com
    Johnson & Johnson (JNJ) Q2 2025 Earnings Call Transcript
    Johnson & Johnson (NYSE:JNJ ) Q2 2025 Earnings Conference Call July 16, 2025 8:30 AM ET Company Participants Darren Snellgrove - Corporate Participant Jennifer L. Taubert - Executive VP & Worldwide Chairman of Innovative Medicine Joaquin Duato - CEO & Chairman John C.
    07/16 15:20 EST - 247wallst.com
    2 Dividend Giants Every Passive Income Investors Should Own
    It's never been easier as a passive income investor to give your yield a bit of a jolt with the rise of covered call (and premium income) ETFs that trade off a bit of upside potential for some premiums.
    07/16 14:56 EST - fool.com
    Johnson & Johnson Lifts 2025 Outlook
    Johnson & Johnson (JNJ 5.93%) reported Q2 2025 earnings on July 16, 2025, posting sales of $23.7 billion (up 4.6%), with adjusted EPS of $2.77 and net earnings of $5.5 billion. Management raised full-year 2025 sales guidance by $2 billion and adjusted EPS guidance by $0.25, citing robust...